ProMIS Neurosciences Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PMN in the last 7 days.
No SEC Form 4 filings for $PMN in the last 30 days.
See all $PMN insider activity →H.C. Wainwright reiterated a Buy rating and $18.00 price target for ProMIS Neurosciences (PMN). The stock trades at $8.70 with a $78M market cap. Analysts cite potential demand for PMN's amyloid-targeting agent due to lower ARIA risks. PMN reported improved cash position in Q2 2026, with CAD 53.4M in reserves, and appointed Ivana Rubino as Chief Commercial Officer.
H.C. Wainwright reiterated a Buy rating and $18.00 price target for ProMIS Neurosciences (PMN) after the company appointed Ivana Rubino as Chief Commercial Officer. PMN trades at $9.61, with InvestingPro noting its undervaluation and strong cash position. The company reported Q2 cash of CAD 53.4 million and a net loss of CAD 11.7 million, expecting funds to last through 2027.
ProMIS Neurosciences (PMN) appointed Ivana Rubino as CCO, effective October 5, 2026. Rubino has 15+ years of biopharmaceutical experience, specializing in Alzheimer’s disease, and previously worked at Biogen (BIIB) and Roche (ROG). She led Alzheimer’s programs, including Leqembi, and global medical strategies.
Recent PMN coverage spans earnings, financial news and technology.
Analyst reiteration may support modest upside as investors price in improved cash position and lower ARIA risk.
Analyst upgrade and cash strength likely support upside momentum.
The new CCO brings extensive Alzheimer’s‑disease experience, which could improve commercial execution for ProMIS's pipeline.
The earnings beat is offset by zero reported revenue, keeping the fundamental signal mixed and likely limiting sustained upside.
Interim safety and target-engagement signals for PMN310 reduce near-term clinical risk and support funding visibility into 2027.
AlphAI scores every news story that mentions PMN with an AI model for sentiment and relevance, and aggregates insider trades from ProMIS Neurosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright reiterated a Buy rating and $18.00 price target for ProMIS Neurosciences (PMN). The stock trades at $8.70 with a $78M market cap. Analysts cite potential demand for PMN's amyloid-targeting agent due to lower ARIA risks. PMN reported improved cash position in Q2 2026, with CAD 53.4M in reserves, and appointed Ivana Rubino as Chief Commercial Officer.
1 min readH.C. Wainwright reiterated a Buy rating and $18.00 price target for ProMIS Neurosciences (PMN) after the company appointed Ivana Rubino as Chief Commercial Officer. PMN trades at $9.61, with InvestingPro noting its undervaluation and strong cash position. The company reported Q2 cash of CAD 53.4 million and a net loss of CAD 11.7 million, expecting funds to last through 2027.
1 min readProMIS Neurosciences (PMN) appointed Ivana Rubino as CCO, effective October 5, 2026. Rubino has 15+ years of biopharmaceutical experience, specializing in Alzheimer’s disease, and previously worked at Biogen (BIIB) and Roche (ROG). She led Alzheimer’s programs, including Leqembi, and global medical strategies.
1 min readPROMIS Neurosciences (PMN) reported Q2 2026 results on Aug. 13. It posted EPS of -$1.28, better than the -$1.39 estimate by $0.11, and revenue of $0, matching estimates. The article also cites insider purchases (7 buys, 0 sells in 6 months), institutional buying by several funds, and a median analyst price target of $18.5.
3 min readProMIS Neurosciences (PMN) reported interim Phase I-B data for PMN310, saying it observed no ARIA-E and showed strong biomarker signals, indicating target engagement and a differentiated safety profile, according to its Q2 2026 audio transcript. The company said cash runway extends through 2027 and a pivotal readout is expected in Q1 2027.
1 min readProMIS Neurosciences reported Q2 2026 results and an earnings call transcript. Cash and short-term investments rose to CAD 53.4 million at June 30, 2026, after a January financing. Q2 net loss was CAD 11.7 million (CAD 1.28/share). Management said funding should last through 2027 for a Q1 2027 PRECISE-AD readout for PMN310.
4 min readProMIS Neurosciences (Nasdaq: PMN) reported Q2 2026 results and interim six-month blinded data from its Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s. It said there were no ARIA-E cases among 136 safety-evaluable participants, and biomarkers pTau217 and CSF MTBR-tau243 declined. Cash was $53.4M, funding operations through 2027, with unblinded 12-month topline expected in Q1 2027.
7 min readProMIS Neurosciences Inc. (PMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights • Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzhe
6 min readKaplan Johanne (Chief Development Officer) purchased 2,280 shares of ProMIS Neurosciences Inc. (PMN) at $13.30 on 2026-08-05.
1 min readProMIS Neurosciences Inc. (Nasdaq: PMN) said it will release its second-quarter 2026 financial results for the period ended June 30, 2026 and provide a business update on Aug. 13, 2026. The company will hold an investor conference call and webcast at 4:30 p.m. ET, with a replay available afterward on its website.
1 min read
